JP2024515829A - 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド - Google Patents

大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド Download PDF

Info

Publication number
JP2024515829A
JP2024515829A JP2023566514A JP2023566514A JP2024515829A JP 2024515829 A JP2024515829 A JP 2024515829A JP 2023566514 A JP2023566514 A JP 2023566514A JP 2023566514 A JP2023566514 A JP 2023566514A JP 2024515829 A JP2024515829 A JP 2024515829A
Authority
JP
Japan
Prior art keywords
compound
subject
pharma
acceptable salt
degrees
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566514A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515829A5 (https=
Inventor
ロバート アルフォンソ ラサー，
ジェイムズ ドハーティ，
ジェフリー マーティン ジョナス，
スティーブン ジェイ ケインズ，
ハンダン グンドゥーズ－ブルース，
ヘレン アン コルクホーン，
ライアン アーノルド，
ビジャイベール ボンサパリー，
ジョイ リサ ダンバー，
バンバン セノアジ アディウィジャヤ，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sage Therapeutics LLC
Original Assignee
Sage Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics LLC filed Critical Sage Therapeutics LLC
Publication of JP2024515829A publication Critical patent/JP2024515829A/ja
Priority to JP2025074660A priority Critical patent/JP2025111701A/ja
Publication of JP2024515829A5 publication Critical patent/JP2024515829A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2023566514A 2021-04-29 2022-04-29 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド Pending JP2024515829A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025074660A JP2025111701A (ja) 2021-04-29 2025-04-28 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド

Applications Claiming Priority (17)

Application Number Priority Date Filing Date Title
US202163181743P 2021-04-29 2021-04-29
US63/181,743 2021-04-29
US202163197025P 2021-06-04 2021-06-04
US63/197,025 2021-06-04
US202163210810P 2021-06-15 2021-06-15
US63/210,810 2021-06-15
US202163239096P 2021-08-31 2021-08-31
US63/239,096 2021-08-31
US202163285812P 2021-12-03 2021-12-03
US63/285,812 2021-12-03
US202163289520P 2021-12-14 2021-12-14
US202163289506P 2021-12-14 2021-12-14
US63/289,520 2021-12-14
US63/289,506 2021-12-14
US202263298601P 2022-01-11 2022-01-11
US63/298,601 2022-01-11
PCT/US2022/026920 WO2022232504A1 (en) 2021-04-29 2022-04-29 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid for use in treating major depressive disorder and postpartum depression

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025074660A Division JP2025111701A (ja) 2021-04-29 2025-04-28 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド

Publications (2)

Publication Number Publication Date
JP2024515829A true JP2024515829A (ja) 2024-04-10
JP2024515829A5 JP2024515829A5 (https=) 2025-05-09

Family

ID=81748925

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2023566514A Pending JP2024515829A (ja) 2021-04-29 2022-04-29 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド
JP2025074660A Pending JP2025111701A (ja) 2021-04-29 2025-04-28 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025074660A Pending JP2025111701A (ja) 2021-04-29 2025-04-28 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド

Country Status (11)

Country Link
US (1) US20240216395A1 (https=)
EP (1) EP4329770A1 (https=)
JP (2) JP2024515829A (https=)
KR (1) KR20240006026A (https=)
AU (1) AU2022266680A1 (https=)
BR (1) BR112023022264A2 (https=)
CA (1) CA3218072A1 (https=)
IL (1) IL307991A (https=)
MX (1) MX2023012727A (https=)
TW (1) TW202308654A (https=)
WO (1) WO2022232504A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2882708A1 (en) 2012-08-21 2014-02-27 Sage Therapeutics, Inc. Methods of treating epilepsy or status epilepticus
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
JOP20200195A1 (ar) 2014-09-08 2017-06-16 Sage Therapeutics Inc سترويدات وتركيبات نشطة عصبياً، واستخداماتها
WO2016082789A1 (en) 2014-11-27 2016-06-02 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MA51046A (fr) 2017-12-08 2021-03-17 Sage Therapeutics Inc Dérivés de 21-[4-cyano-pyrazol-1-yl]-19-nor-pregan-3. alpha-ol-20-one deutérés pour le traitement de troubles du snc

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof
JP2020533310A (ja) * 2017-09-07 2020-11-19 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイドおよびそれらの使用方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102396328B1 (ko) 2013-04-17 2022-05-10 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드 및 그의 사용 방법
EP3504189A1 (en) 2016-08-23 2019-07-03 Sage Therapeutics, Inc. A crystalline 19-nor c3, 3-disubstituted c21-n-pyrazolyl steroid
MX2021006985A (es) * 2018-12-14 2021-09-08 Praxis Prec Medicines Inc Metodos para el tratamiento de la depresión.
KR20230041049A (ko) 2020-07-20 2023-03-23 세이지 테라퓨틱스, 인크. 19-노르 c3,3-이치환된 c21-n-피라졸릴 스테로이드의 제형 및 이의 사용 방법
IL315023A (en) * 2022-02-16 2024-10-01 Sage Therapeutics Inc Neuroactive steroids for treatment of cns-related disorders

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020533310A (ja) * 2017-09-07 2020-11-19 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイドおよびそれらの使用方法
WO2019241442A1 (en) * 2018-06-12 2019-12-19 Sage Therapeutics, Inc. A 19-nor c3,3-disubstituted c21 -n-pyrazolyl steroid and methods of use thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL PSYCHIATRY, vol. 87, JPN6026009185, 2020, pages 9 - 278, ISSN: 0005811300 *
EUROPEAN NEUROPSYCHOPHARMACOLOGY, vol. 40, JPN6026009184, 2020, pages 1 - 177, ISSN: 0005811299 *
NEUROPSYCHOPHARMACOLOGY, vol. 44, JPN6026009186, 2019, pages 426 - 427, ISSN: 0005811301 *
THE NEW ENGLAND JOURNAL OF MEDICINE, vol. 381, no. 10, JPN6026009187, 2019, pages 903 - 911, ISSN: 0005811302 *

Also Published As

Publication number Publication date
US20240216395A1 (en) 2024-07-04
TW202308654A (zh) 2023-03-01
MX2023012727A (es) 2023-11-08
KR20240006026A (ko) 2024-01-12
IL307991A (en) 2023-12-01
WO2022232504A1 (en) 2022-11-03
JP2025111701A (ja) 2025-07-30
CA3218072A1 (en) 2022-11-03
BR112023022264A2 (pt) 2024-01-23
EP4329770A1 (en) 2024-03-06
AU2022266680A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
JP2024515829A (ja) 大うつ病性障害および産後うつ病の処置における使用のための１９－ノルｃ３，３－二置換ｃ２１－ｎ－ピラゾリルステロイド
US20250339447A1 (en) 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
KR20240148425A (ko) Cns-관련 장애의 치료를 위한 신경활성 스테로이드
US20230018765A1 (en) A 19-nor c3,3-disubstituted c21-n-pyrazolyl steroid and methods of use thereof
CN108135865A (zh) 使用芬氟拉明治疗Lennox-Gastaut综合征的方法
CN113825510A (zh) 使用氘化右美沙芬和奎尼丁治疗精神分裂症的阴性症状的方法
CN118416069A (zh) 用卡博特韦和利匹韦林治疗hiv的方法
CN117580581A (zh) 用于治疗重度抑郁障碍和产后抑郁症的19-去甲c3,3-二取代的c21-n-吡唑基类固醇
WO2025122747A1 (en) Treatment of moderate-to-severe asthma by administering rilzabrutinib
CN120981229A (zh) 用于治疗先天性肾上腺皮质增生症的组合物和方法
WO2023159035A1 (en) Neuroactive steroids for treatment of cns-related disorders
HK40060751A (en) Methods of treating negative symptoms of schizophrenia using deuterated dextromethorphan and quinidine

Legal Events

Date Code Title Description
A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20250428

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250428

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260220

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260306